
    
      The original base protocol (V501-018)(NCT00092547) was extended in amendments V501-018-05 and
      -06 to provide 37 months of follow-up. Additionally, subjects in the Placebo Group during the
      base study were given 3 doses of open-label GARDASILâ„¢ (V501) at Months 30, 32, and 36.

      The study was extended again in amendment V501-018-10(NCT00092547), titled "A Long Term
      Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6,
      11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of
      Age" to allow a follow-up period to Month 126.
    
  